Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Alpaslan Özgün"'
Autor:
Bülent Karagöz, Alpaslan Özgün, Levent Emirzeoğlu, Tolga Tunçel, Serkan Çelik, Oğuz Bilgi, Kemal Kara
Publikováno v:
European Journal of Breast Health, Vol 11, Iss 1, Pp 48-51 (2015)
Lapatinib is an effective drug in HER2-positive breast cancer. We present a case with successful treatment of lapatinib in brain metastasis of HER2+ breast cancer. Forty-eight years old woman was admitted our clinic with early breast cancer. In third
Externí odkaz:
https://doaj.org/article/07a5a35524b7478191a81ffa7bfb157c
Publikováno v:
Journal of the Egyptian National Cancer Institute, Vol 27, Iss 3, Pp 161-163 (2015)
The prognosis of metastatic melanoma is poor. Pre-targeted treatment era, the combination of interferon-α (IF-α) plus chemotherapy had been used and have generally short response duration. Herein, we present a metastatic melanoma case that achieved
Externí odkaz:
https://doaj.org/article/eaf578311c144b51b0a3b16980bd499c
Autor:
Mutlu Hizal, Burak Bilgin, Nail Paksoy, Saadettin Kılıçkap, Muhammed Mustafa Atcı, Seda Kahraman, Merve Keskinkılıç, İrem Bilgetekin, Murat Ayhan, Deniz Tural, Önder Eren, Fatma Nihan Akkoç Mustafayev, Şebnem Yaman, Ali Murat Tatlı, Ertuğrul Bayram, Yasin Kutlu, İsmail Ertürk, Erkan Özcan, Ahmet Gülmez, Mustafa Korkmaz, Baran Akagündüz, Dilek Erdem, Tuğba Akın Telli, Asude Aksoy, Necdet Üskent, Yakup İriağaç, Naziyet Köse Baytemür, Dinçer Aydın, Teoman Şakalar, Hacı Arak, Fatih Selçukbiricik, Yakup Ergün, Taner Korkmaz, Naziye Ak, Çağlar Ünal, Nadiye Akdeniz, Mehmet Alpaslan Özgün, Berna Öksüzoğlu, Bülent Yalçın, İlhan Öztop, Efnan Algın, Abdullah Sakin, Adnan Aydıner, Perran Fulden Yumuk, Mehmet Ali Nahit Şendur
Publikováno v:
Future Oncology. 18:2573-2582
Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043d1a22a8f3e83e986a7039a57bac7a
https://doi.org/10.2217/fon-2022-0083
https://doi.org/10.2217/fon-2022-0083
Autor:
Mutlu Hizal, Burak Bilgin, Nail Paksoy, Muhammed Mustafa Atcı, Seda Kahraman, Saadettin Kılıçkap, Merve Keskinkılıç, Murat Ayhan, Önder Eren, Fatma Nihan Akkoç Mustafayev, Şebnem Yaman, Ertuğrul Bayram, İsmail Ertürk, Erkan Özcan, Mustafa Korkmaz, Baran Akagündüz, Dilek Erdem, Tuğba Akın Telli, Asude Aksoy, Necdet Üskent, Naziyet Köse Baytemür, Ahmet Gülmez, Dinçer Aydın, Teoman Şakalar, Hacı Arak, Ali Murat Tatlı, Yakup Ergün, Naziye Ak, Çağlar Ünal, Mehmet Alpaslan Özgün, Bülent Yalçın, İlhan Öztop, Efnan Algın, Abdullah Sakin, Adnan Aydıner, Perran Fulden Yumuk, Mehmet Ali Nahit Şendur
Introduction: Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage of ALK-positive tumor cells i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb3cc0c537f79435ee24f92ba6ab7f9b
https://doi.org/10.21203/rs.3.rs-1583429/v1
https://doi.org/10.21203/rs.3.rs-1583429/v1
Publikováno v:
Experimental dermatologyREFERENCES. 31(1)
The development of brain metastases is the deadliest complication of advanced melanoma, and has long been associated with a dismal prognosis. The recent years have seen incredible progress in the development of therapies for melanoma brain metastases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::555df6abc221f15e12822ee641ed9df7
https://pubmed.ncbi.nlm.nih.gov/33455008
https://pubmed.ncbi.nlm.nih.gov/33455008
Autor:
Alpaslan Özgün, Zeynep Eroglu
Publikováno v:
Expert Opinion on Orphan Drugs. 6:545-551
INTRODUCTION: Breakthroughs in targeted therapy have significantly improved outcomes for many patients with advanced melanoma, including those with BRAFV600 mutant disease. Targeted therapy for BRAFV600-mutant metastatic melanoma includes combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::705d5b35c5839a3464ca2958ff20876a
https://doi.org/10.1080/21678707.2018.1512402
https://doi.org/10.1080/21678707.2018.1512402
Autor:
Tolga Tuncel, Cihan Top, Alpaslan Özgün, Bülent Karagöz, Levent Emirzeoglu, Tuba Muftuoglu, Oguz Bigi, Caner Cam, Serkan Celik
Publikováno v:
Contemporary Oncology
Contemporary Oncology, Vol 20, Iss 3, Pp 215-219 (2016)
Contemporary Oncology, Vol 20, Iss 3, Pp 215-219 (2016)
Aim of the study: Interleukin (IL)-17 and IL-23 play roles in inflammation and autoimmunity. The function of the IL-17/IL-23 pathway has not been completely evaluated in cancer patients. We aimed to investigate serum IL-17 and IL-23 levels and their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74fc210e8d50687f2df567de0203a6e1
https://doi.org/10.5114/wo.2016.61562
https://doi.org/10.5114/wo.2016.61562
Autor:
Michael J. Allegrezza, Gretchen M. Alicea, Nikolaos Svoronos, Theodore S. Nowicki, Amanpreet Kaur, Rami N. Al-Rohil, Antoni Ribas, Stephen M. Douglass, Richard Marais, Jennifer L. McQuade, Zeynep Eroglu, Alpaslan Özgün, Iman Osman, Michael A. Davies, Dmitry I. Gabrilovich, Rajasekharan Somasundaram, Jose R. Conejo-Garcia, Farbod Darvishian, Abibatou Ndoye, Matteo S. Carlino, Mitchell Fane, Siwen Hu-Lieskovan, Curtis H. Kugel, Xiangfan Yin, Ravi K. Amaravadi, Bastian Schilling, Marie R. Webster, Dirk Schadendorf, Reeti Behera, Qin Liu, Sarah A. Weiss, Rajat Rai, Ashani T. Weeraratna, Eric A. Stone, Daniel Y. Wang, Jeffrey A. Sosman, Brett L. Ecker, Wei Xu, Vinit Kumar, Alexander M. Menzies, Douglas B. Johnson, Meenhard Herlyn, Georgina V. Long
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 21
Purpose: We have shown that the aged microenvironment increases melanoma metastasis, and decreases response to targeted therapy, and here we queried response to anti-PD1. Experimental Design: We analyzed the relationship between age, response to anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e92c637dcfb0cb73341fad03201f5dc
https://europepmc.org/articles/PMC6324578/
https://europepmc.org/articles/PMC6324578/
Autor:
F. Stephen Hodi, Jason J. Luke, Elizabeth I. Buchbinder, Paul Leger, Richard W. Joseph, Fei Ye, Daniel Y. Wang, Rizwan Haq, Jeffrey A. Sosman, Zeynep Eroglu, Alpaslan Özgün, Shilin Zhao, Douglas B. Johnson, Patrick A. Ott
Anti–PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti–PD-1. We retrospectively reviewed 488 patients treated with anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31445cdc384b37272d7330b860af374c
https://europepmc.org/articles/PMC5502536/
https://europepmc.org/articles/PMC5502536/
Autor:
Meredith Ann McKean, Eileen Shiuan, Michael A. Postow, John P. Greer, Kathryn E. Beckermann, Ciara Marie Kelly, Michael A. Davies, Douglas B. Johnson, Zeynep Eroglu, Igor Puzanov, Alpaslan Özgün, Jennifer L. McQuade, Suthee Rapisuwon, Mary Ann Thompson
Publikováno v:
Journal for Immunotherapy of Cancer
Background Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-related adverse events (irAEs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce7a050213d261a9baf992f7f6b1848e
http://europepmc.org/articles/PMC5319013
http://europepmc.org/articles/PMC5319013